Nintedanib: beneficial agent in post-COVID-19 Pulmonary Fibrosis

1 Hosseini, E.S.; Kashani, N.R.; Nikazad, H. The novel coronavirus Disease-2019 (COVID-2019): Mechanism of action, detection and recent therapeutic strategies. Virology. 2020. 551:1-9. Search in Google Scholar

2 Cucianotta, D.; Vanelli, M. WHO declares COVID-19 a pandemic. Biomed. 2020;91:157–160. Search in Google Scholar

3 Huang, C.; Wang, Y.; Li, X.; Clinical features of patients infected with 2019 nocel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. DOI:10.1016/s0140-6736(20)30183-5 Search in Google Scholar

4 Kong, S.L.; Lim, B.; et al.; Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients. Virus Res. 2009;145(2):260–269. Search in Google Scholar

5 Lee, E.J.; Lim, J.Y.; Lee, S.Y.; el al. The expression of HSPs, anti-oxidants, and cytokines in plasma and bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. Clin Biochem. 2012;45(6):493–498. Search in Google Scholar

6 Li-Jane, S.; Chun-Chun Yang,; Min-Tser, L.; et al; An importan call: call Suggestion of using IL-10 as therapeutic agent for COVID-19 with ARDS and other complications. Virulence. 2023; doi.org/10.1080/21505594.2023.2190650 Search in Google Scholar

7 Wigen, J.; Lofdahl, A.; Bjermer, L.; el al,; Converging pathways in pulmonary fibrosis and Covid-19 – The fibrotic link to desease severity. Respir Med X. 2020;2;100023, Search in Google Scholar

8 McDonald, L.T.; Healinh after COVID-19: are survivors at risk for pumonary fibrosis? Am J Phusiol Lung Cell Mol Physiol. 2021;320:0–65. Search in Google Scholar

9 Furuhashi, M.; Moniwa, N.; Takizawa, H.; Potential differential effects of renin-angiotensin system inhibitors on SARSCoV- 2 infection and lung injury in COVID-19. Hypertens. Res. 2020;43:837–840. Search in Google Scholar

10 Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; SARS-CoV-2 cell entry depends on ACE2 and TMPRESS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280 e278. Search in Google Scholar

11 Zhang, H.; Shang, W.; Liu, Q.; infection, China : 2020. Clinical Characteristics of 194 Cases of COVID-19 in Huanggang and Taian. Search in Google Scholar

12 Nalysnyk, L.; Cid-Ruzafa, J.; Rotella, R.; Esser, D.; Incidence and prevalence of idiopathic pulmonary fibrosis: a literature review. Eur Respir Rev. 2012;21:355–361. Search in Google Scholar

13 Hutchinson, J.; Fogarty, A.; Hubbard, R.; McKeever, T.; Global incidence and mortality of idiopathic pulmonary fibrosis: a system review. Eur Respir J. 2015;46:795–806. Search in Google Scholar

14 King TE, Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–2092. Search in Google Scholar

15 Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082. Search in Google Scholar

16 George, P.M.; Wells, A.U.; Jenkins, R.G.; Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8:807–815. Search in Google Scholar

17 Seifirad, S.; Pirfenidone: a novel hypothetical treatment for COVID-19, Seifirad S. Med Hypotheses. 2020;144: 110005. Search in Google Scholar

18 Grześk, G.; Woźniak-Wiśniewska, A.; Błażejewski, J.; Górny, B.; The interactions of nintedanib and oral anticoagulantsmolecular mechanisms and clinical implications, Int J Mol Sci. 2020;22:282. Search in Google Scholar

19 Zhang, T.; Sun, LX.; Feng, R.E.; [Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019] Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:e040. Search in Google Scholar

20 Herridge, M.S.; Tansey, C.M.; Matté, A.; et al. Functional disability five years after acute respiratory distress syndrome. N Engl J Med. 2011;364:1293–1304. Search in Google Scholar

21 Burnham, E.L.; Janssen, W.J.; Riches, D.W.; Moss, M.; Downey, G.P.; The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. Eur Respir J. 2014;43:276–285. Search in Google Scholar

22 Le, T.T.; Karmouty-Quintana, H.; Melicoff, E.; et al. Blockade of IL-6 trans signaling attenuates pulmonary fibrosis. J Immunol. 2014;193:3755–3768. Search in Google Scholar